Lumbrokinase: The Fibrinolytic Enzyme for Circulation & Joint Mobility

What is Lumbrokinase?

Lumbrokinase is a serine protease enzyme complex extracted from the earthworm Lumbricus rubellus. It belongs to the fibrinolytic enzyme family—compounds that break down fibrin, a key structural protein in blood clots. Lumbrokinase is manufactured through fermentation and purification of earthworm tissue, and is also known by the brand name Boluoke.

The enzyme works by directly cleaving fibrin molecules and activating plasminogen, the inactive precursor to plasmin (the body's main clot-dissolving enzyme). This dual mechanism allows lumbrokinase to theoretically support the body's natural fibrinolytic pathways without being a direct anticoagulant in the pharmaceutical sense. Once ingested, proteolytic enzymes face significant digestive challenges; much of lumbrokinase is broken down in the stomach and small intestine, though enteric-coated formulations may improve bioavailability by protecting the enzyme until it reaches the small intestine.

Lumbrokinase has been used in traditional Chinese and Japanese medicine for centuries and is approved as a pharmaceutical agent in China and parts of Asia. In the West, it is sold as a dietary supplement.

Evidence-based benefits of Lumbrokinase

Research on lumbrokinase in human subjects is limited but growing. Most clinical data comes from small trials conducted in Asia. Below are the primary areas under investigation.

Circulation & Fibrinolytic Activity

The core mechanism of lumbrokinase is fibrinolytic—breaking down excess fibrin to maintain healthy clot resolution. Small clinical trials suggest lumbrokinase may promote fibrinolytic activity and support healthy blood viscosity. Several studies in Asian populations reported improvements in blood flow parameters and reductions in fibrin markers after lumbrokinase supplementation, typically at doses of 10–20 mg daily for 2–12 weeks. However, most trials are small, lack robust blinding, and are published primarily in non-English journals, limiting the certainty of conclusions for Western clinical practice.

Joint Mobility & Inflammation

Proteolytic enzymes are hypothesized to reduce inflammation and support connective tissue remodeling. A handful of small studies suggest lumbrokinase may support joint comfort and mobility, possibly through anti-inflammatory pathways and improved local circulation. Evidence is preliminary and largely indirect; no large, well-controlled RCTs in Western populations specifically isolate lumbrokinase's joint benefits.

Post-Thrombotic Syndrome & Vascular Health

One small RCT published in Chinese medical journals suggested lumbrokinase supplementation may support recovery from deep vein thrombosis (DVT) and post-thrombotic symptoms when used alongside standard care. The sample sizes were small and follow-up periods brief. More rigorous Western trials would be needed to establish clinical significance.

Atherosclerosis Prevention

Very preliminary in vitro and animal evidence suggests lumbrokinase may help prevent atherosclerotic plaque buildup by supporting fibrinolysis and reducing platelet aggregation. No human clinical trials have demonstrated cardiovascular event reduction. This remains a theoretical benefit pending robust evidence.

Supplement forms of Lumbrokinase, compared

Lumbrokinase is available primarily as a standardized enzyme extract in capsule or tablet form, often standardized to fibrinolytic units (FU) or activity units. Most commercial products use enteric coating to protect the enzyme from stomach acid and optimize small-intestinal absorption. Dosing and standardization vary widely among brands; look for products that specify enzyme activity (typically 10–60 mg daily in clinical studies).

How much Lumbrokinase should you take?

Lumbrokinase dosing in published clinical trials typically ranges from 10 to 20 mg daily, split into one to three doses. Some formulations recommend higher intakes (up to 60 mg daily), but evidence supporting efficacy at higher doses is limited. No official RDA or UL exists, as lumbrokinase is not a nutrient.

• Standard supplemental dose: 10–20 mg daily for general circulation and joint support, taken in divided doses with meals.
• Higher clinical doses: Up to 40–60 mg daily in some Asian studies, though evidence for superiority is unclear.
• Duration: Most clinical trials ran 4–12 weeks; long-term safety data beyond 12 weeks is sparse.

Enteric-coated formulations should be swallowed whole and taken on an empty stomach or as directed on the label to prevent premature digestion in the stomach. If combining with other proteolytic enzymes or anticoagulant herbs, consult a clinician to avoid redundant dosing. Lumbrokinase is most effective when used consistently over several weeks.

Safety, side effects, and risks

Lumbrokinase is generally well tolerated at recommended doses. It has been used for decades in Asian countries with a favorable safety profile. However, because it has fibrinolytic and antiplatelet properties, caution is warranted in specific medical contexts. A clinician should be consulted before starting lumbrokinase if you have any bleeding disorder, are taking anticoagulants, or have a history of hemorrhagic stroke.

Common Side Effects

Mild gastrointestinal upset, including nausea, stomach discomfort, or loose stools, may occur. These effects are typically transient and often resolve with continued use or dose reduction. Allergic reactions are rare but possible, especially in individuals with shellfish or insect allergies.

Bleeding Risk

Because lumbrokinase activates fibrinolysis and may have antiplatelet effects, there is a theoretical risk of increased bleeding or bruising, particularly at high doses or when combined with anticoagulant medications (warfarin, direct oral anticoagulants) or antiplatelet drugs (aspirin, clopidogrel). Although clinical hemorrhagic events are rare in reported trials, the risk warrants medical oversight before use in these populations.

Pregnancy & Lactation

Safety in pregnancy and nursing has not been established. Lumbrokinase's fibrinolytic activity could theoretically raise miscarriage risk. Pregnant or lactating women should avoid lumbrokinase unless explicitly cleared by their healthcare provider.

YMYL Caution

This information is educational and does not replace medical advice. If you have cardiovascular disease, clotting disorders, or take blood thinners, talk to your doctor or pharmacist before starting lumbrokinase. Do not use lumbrokinase as a replacement for prescribed anticoagulant therapy without medical supervision.

Drug and nutrient interactions

• Warfarin and other vitamin K antagonists: Lumbrokinase may potentiate anticoagulant effect, increasing bleeding risk. Medical supervision and INR monitoring are essential if co-use is considered.
• Direct oral anticoagulants (DOACs) — apixaban, rivaroxaban, dabigatran: Co-administration with lumbrokinase theoretically increases bleeding risk. Avoid without explicit clinician approval.
• Aspirin and antiplatelet agents: Combined use may increase bleeding or bruising risk, especially at higher lumbrokinase doses. Consult a clinician before combining.
• Other fibrinolytic or proteolytic enzymes — nattokinase, bromelain, papain: Stacking multiple fibrinolytic enzymes may increase bleeding risk and is not well studied. Avoid redundant supplementation unless guided by a practitioner.
• NSAIDs (ibuprofen, naproxen): Some evidence suggests combined use with fibrinolytic enzymes may slightly increase GI irritation risk. Take together with food and monitor for stomach upset.
• Herbs with anticoagulant properties — garlic, ginger, ginkgo biloba: Theoretical additive bleeding risk; medical guidance is prudent before combining multiple blood-thinning agents.

For a comprehensive review of your specific medications and supplements, use our interaction checker tool.

Who might benefit — and who shouldn't self-supplement without guidance

Frequently asked questions

Related ingredients